NYX-2925 Continues to Significantly Reduce Pain Severity Marker in Phase 2 Trial, Top Line Data Shows

NYX-2925 Continues to Significantly Reduce Pain Severity Marker in Phase 2 Trial, Top Line Data Shows
Aptinyx's NYX-2925 treatment candidate continues to significantly reduce the levels of a brain biomarker associated with pain severity, called glutamine (Glx), in people with fibromyalgia, top line results of a Phase 2 pilot trial show. The findings also showed improvements in patient-reported pain, as well as a reduction in fibromyalgia’s impact on daily living. “The statistically significant effects on both pain-related brain activity and patient-reported clinical measures elegantly demonstrates that NYX-2925 is acting in the brain to alter pain processing, leading to pain alleviation,” Norbert Riedel, president and CEO of Aptinyx, said in a press release. “The results with NYX-2925 are compelling and compare very favorably with the effects of approved fibromyalgia drug treatments we previously evaluated in separate and similar studies,” added Daniel Clauw, an investigator in this trial
Subscribe or to access all post and page content.